Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + anlotinib + etoposide + cisplatin
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Tislelizumab + anlotinib + etoposide + cisplatin is a combination chemo-immunotherapy regimen primarily investigated for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and other neuroendocrine malignancies. The regimen combines tislelizumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, with anlotinib, an oral multi-targeted receptor tyrosine kinase inhibitor (TKI) targeting VEGFR, PDGFR, FGFR, and c-Kit, alongside standard-of-care chemotherapy consisting of etoposide (a topoisomerase II inhibitor) and cisplatin (a platinum-based alkylating agent). This combination aims to enhance anti-tumor efficacy by leveraging the synergistic effects of immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy to overcome resistance and improve survival outcomes in aggressive, highly proliferative cancers.
- Other names
- tislelizumab + anlotinib + EPtislelizumab + anlotinib + EP regimentislelizumab + anlotinib + etoposide + cisplatintislelizumab + anlotinib + etoposide + cisplatin regimen
02
Targets
DNATOP2A (DNA topoisomerase II)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on tislelizumab + anlotinib + etoposide + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + anlotinib + etoposide + cisplatin.